Transcript for Pfizer reports data on 3-dose COVID-19 vaccine for children under five
- In a major step forward for parents looking to protect the youngest of children, Pfizer tonight saying its vaccine for children 5 and under is 80% effective against symptomatic Omicron. The FDA will review now both Pfizer's application and Moderna's application for the youngest children June 15. There are some 18 million children younger than five not yet eligible for vaccination against the coronavirus. Both Pfizer and Moderna doses much smaller than the ones, of course, used at adults.
Pfizer's is a three-shot regimen. It all comes as cases rise nationwide. 105,000 new cases reported every day now, that's four times higher than what we were seeing just last month. And when it comes to children, more than 107,000 testing positive in just the last week. Philadelphia, in fact, reinstating the mask mandate in the city's public schools. And with the FDA set to examine these child vaccines mid-June, how soon will parents have access to them?
ABC'S Stephanie Ramos leading us off this Monday night.
- Give mommy hug and kiss.
STEPHANIE RAMOS: Tonight, Pfizer releasing the data some parents of young children have been waiting for.
- Good girl.
STEPHANIE RAMOS: The company reporting its three-shot vaccine is 80% effective against symptomatic Omicron in children under five.
- That'll be up to the FDA in June to determine if this antibody response is sufficient enough to protect against severe illness and hospitalization.
STEPHANIE RAMOS: The Pfizer vaccine for the youngest children is a tenth of the dose for those 12 and older and will be given in three doses after data showed two were not effective.
- When the first vaccines were designed, that was pretty Omicron. We're in a completely different era now, where three doses are likely what's necessary to give an adequate immune response.
STEPHANIE RAMOS: Moderna is already asking for authorization for its two-shot shot vaccine for kids under six. But after data showed efficacy was 51% or less, the company is now testing a third shot. An FDA review of the pediatric Pfizer and Moderna vaccines now scheduled for June 15. For many parents, a vaccine can't come soon enough.
- One, two, three.
STEPHANIE RAMOS: Meagan Dunphy-Daly enrolled two of her kids in the Pfizer trial.
- To see the rest of the world move on has been really, has been a really big challenge for many of us. So we are eagerly awaiting good news.
STEPHANIE RAMOS: It comes as more than 170,000 children tested positive for COVID last week, the highest since February. Today, Philadelphia bringing back its mask mandate in public schools.
- As the cases were rising, I figured the school probably will do something.
STEPHANIE RAMOS: Several cities, including New York City, Milwaukee, and Boston seeing an uptick for weeks, now recommending but not mandating masks indoors.
- So let's get back to those vaccines, Steph. The FDA meeting now and the vaccines for the youngest children in the US in the coming weeks here so how soon before parents could get their children of five and under now vaccinated?
- Very soon, David. That FDA meeting is expected On June 15th. If the FDA authorizes both Pfizer's and Moderna's pediatric vaccines, then it's off to the CDC for their review. So a vaccine for kids under the age of five could be given the all clear by late June or early July if everything goes as planned, David.
- All right, Stephanie Ramos leading us off here. Stephanie, thank you.
This transcript has been automatically generated and may not be 100% accurate.